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Abstract
Background: Many breast, pancreatic, colonic and non-small-cell lung carcinoma lines express
CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen, CEA), and antibodies to both
can affect tumor cell growth in vitro and in vivo. Here, we compare both antigens as a function of
histological phenotype in breast, pancreatic, lung, ovarian, and prostatic cancers, including patient-
matched normal, primary tumor, and metastatic breast and colonic cancer specimens.
Methods:  Antigen expression was determined by immunohistochemistry (IHC) using tissue
microarrays with MN-15 and MN-3 antibodies targeting the A1B1- and N-domains of CEACAM6,
respectively, and the MN-14 antibody targeting the A3B3 domain of CEACAM5. IHC was
performed using avidin-biotin-diaminobenzide staining. The average score ± SD (0 = negative/8 =
highest) for each histotype was recorded.
Results: For all tumors, the amount of CEACAM6 expressed was greater than that of CEACAM5,
and reflected tumor histotype. In breast tumors, CEACAM6 was highest in papillary > infiltrating
ductal > lobular > phyllodes; in pancreatic tumors, moderately-differentiated > well-differentiated
> poorly-differentiated tumors; mucinous ovarian adenocarcinomas had almost 3-fold more
CEACAM6 than serous ovarian adenocarcinomas; lung adenocarcinomas > squamous tumors; and
liver metastases of colonic carcinoma > primary tumors = lymph nodes metastases > normal
intestine. However, CEACAM6 expression was similar in prostate cancer and normal tissues. The
amount of CEACAM6 in metastatic colon tumors found in liver was higher than in many primary
colon tumors. In contrast, CEACAM6 immunostaining of lymph node metastases from breast,
colon, or lung tumors was similar to the primary tumor.
Conclusion: CEACAM6 expression is elevated in many solid tumors, but variable as a function of
histotype. Based on previous work demonstrating a role for CEACAM6 in tumor cell migration,
invasion and adhesion, and formation of distant metastases (Blumenthal et al., Cancer Res 65:
8809–8817, 2005), it may be a promising target for antibody-based therapy.
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Background
The human carcinoembryonic antigen (CEA) family has 7
genes belonging to the CEACAM subgroup. These sub-
group members are mainly associated with the cell mem-
brane and show a complex expression pattern in normal
and cancerous tissues. The CEACAM5 gene, also known as
CD66e, codes for the protein, CEA [1,2]. CEACAM5 was
first described in 1965 as a gastrointestinal oncofetal anti-
gen [3], but is now known to be overexpressed in a major-
ity of carcinomas, including those of the gastrointestinal
tract, the respiratory and genitourinary systems, and
breast cancer [4-8]. CEACAM6 (also called CD66c or
NCA-90) is a non-specific cross-reacting glycoprotein
antigen that shares some antigenic determinants with
CEACAM5 [9]. CEACAM6 also is expressed on granulo-
cytes and epithelia from various organs, and has a broader
expression zone in proliferating cells of hyperplastic
colonic polyps and adenomas, compared with normal
mucosa [10], as well as by many human cancers [10-12].
Relatively high serum levels of CEACAM6 are found in
patients with lung, pancreatic, breast, colorectal, and
hepatocellular carcinomas. The amount of CEACAM6
does not correlate with the amount of CEACAM5
expressed [11].
Expression of CEACAM6 in colorectal cancer correlates
inversely with cellular differentiation [13] and is an inde-
pendent prognostic factor associated with a higher risk of
relapse [14]. Both CEACAM5 and CEACAM6 have a role
in cell adhesion, invasion and metastasis. CEACAM5 has
been shown to be involved in both homophilic (CEA to
CEA) and heterophilic (CEA binding to non-CEA mole-
cules) interactions [15-17], suggesting to some that it is an
intercellular adhesion molecule involved in cancer inva-
sion and metastasis [18-20]. These reactions were com-
pletely inhibited by the Fab' fragment of an anti-
CEACAM5 antibody [16]. CEACAM6 also exhibits homo-
typic binding with other members of the CEA family and
heterotypic interactions with integrin receptors [17]. Anti-
bodies that target the N-domain of CEACAM6 interfere
with cell-cell interactions [21]. We have reported previ-
ously that many breast, pancreatic, colonic and non-
small-cell lung cancer (NSCLC) cell lines express
CEACAM6, and that anti-CEACAM6 antibody inhibits in
vitro migration, invasion, and adhesion of antigen-posi-
tive cells [22]. Therefore, the ability to interfere with
CEACAM6-mediated homotypic and heterotypic binding
might have beneficial anti-metastatic effects.
The goals of the current study were to: (1) use tissue
microarray analysis to compare the relative expression of
CEACAM5 and CEACAM6 in different histotypes of solid
tumors, and (2) develop additional supportive evidence
for a role for CEACAM6 in metastasis by comparing
expression between primary sites and matched metastases
in the same patients. This is the first such comparison of
these two CEACAM antigens in such matched patient
specimens.
Methods
Antibodies
MN-15 binds to the A1B1-domain (Gold group 4) and
MN-3 [22] binds to the N-domain (Gold group 5) found
on both CEACAM5 and CEACAM6 [23]. MN-14 binds to
the A3B3 domain (Gold group 3) only found on
CEACAM5 [24]. These antibodies have similar affinities
for their target antigens [25]. These antibodies, and the
non-specific Ag8 IgG, were supplied by Immunomedics,
Inc. (Morris Plains, NJ). MN-3 and MN-15 were used as
murine MAbs, while MN-14 was included in its human-
ized form, hMN-14 or labetuzumab [26].
Tissue microarrays
AccuMax tissue arrays were purchased from ISUABXIS
through Accurate Chemical & Scientific Corp (Westbury,
NY). The following arrays were used: Breast A202 (II),
colon with matching liver metastases A203 (II), lung
A206, pancreatic (A207), prostate A208, and ovary A213.
Additional breast (BR1001), colorectal (C0991), and lung
(LC810) arrays of matching primary tumor and lymph
node metastases were purchased from US Biomax, Inc.
(Rockville, MD). All arrays consisted of duplicate cancer
tissue cores of varying histotypes and four non-neoplastic
corresponding samples on each slide. There were 45
breast, 40 lung, 26 pancreatic, 40 prostate, and 45 ovarian
cancer specimens (Table 1). Some histotypes are well rep-
resented (e.g., 30 infiltrating ductal breast tumors, while
others have only 3–6 cores per histotype. The metastasis
arrays consisted of the following matched cases: 18 nor-
mal colon, primary colon cancer and liver metastases, 38
breast and lymph node metastases, 33 colon and lymph
node metastases, and 37 lung and lymph node metas-
tases.
Immunohistochemistry
Slides were deparaffinized in xylene, rehydrated, and
treated with fresh 0.3% hydrogen peroxide in methanol
for 15 min. Following a wash in 1× phosphate-buffered
saline (PBS, pH 7.4), slides were blocked with normal
serum in a humid chamber for 20 min at room tempera-
ture (RT). Excess serum was rinsed off with 1× PBS and
slides were incubated in a humid chamber with 25–50 µl
of primary antibody (10 µg/ml) for 45 min at RT. For
CEACAM5 staining, the primary antibody was murine
mMN-14 IgG. For CEACAM6 staining, slides were first
blocked with humanized hMN-14 IgG and then incu-
bated with primary antibody, either murine mMN-15 or
mMN-3 IgG. Excess primary antibody was washed off and
sections were covered with biotinylated goat-anti-mouse
(Vectastain ABC kit) for 30 min in humid chamber at RT.BMC Cancer 2007, 7:2 http://www.biomedcentral.com/1471-2407/7/2
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Slides were then flooded with 0.3% H2O2 in methanol
and 25 µl avidin-horseradish peroxidase (HRP) conjugate
(ABC) was added. Slides were incubated for 45 min at RT,
washed in 1× PBS, and covered with 100 µl 3,3'-diami-
nobenzidine tetrahydrochloride solution (100 mg/ml
diaminobenzide in 0.1 M sodium acetate buffer, pH 6.0,
with 0.01% (v/v) H2O2) for 15 min. Slides were washed
twice by dipping in tap water and counterstained with 4
quick dips in hematoxylin (filtered through Whatman #4
filter paper). Slides were rinsed, air-dried, and mounted
with 1–2 drops of cytoseal and a glass coverslip. The
method of Kawai was used to calculate a semi-quantita-
tive score from 0 to 8 for staining of each tissue core. The
number of positive cells/filed was estimated and assigned
a number: 0 = none, 1 = 1/100 cells, 2 = 1/100 to 1/10
cells, 3 = 1/10 to 1/3 cells, 4 = 1/3 to 2/3 cells, and 5 = >2/
3 cells. The intensity of staining was then determined
where 0 = none, 1 = weak, 2 = intermediate, and 3 =
strong. The first and second scores were then added
together resulting in a maximum staining score of 8 for
any tissue core [27]. Two independent blinded investiga-
tors (author 1 and 2) performed IHC analysis and results
were strongly consistent between the two readings.
Results were recorded as the mean ± standard deviation
for each group. Comparisons between CEACM5 and
CEACAM6 scores for a given histotype or between histo-
types for each antigen were assessed by a one-factor anal-
ysis of variance with the use of a two-tailed F test and a
95% confidence limit. The null hypothesis Ho: µ1 = µ2 =
1/4  µk, where k  equals the number of experimental
groups, was used. A two-tailed test takes into account an
extreme value in any one group that deviates from the
population mean in either the high or low direction (two-
sided). The F value is a measure of the probability that this
difference in groups could occur by chance alone.
Results
Expression in solid tumors as a function of histotype
For all tumor cores evaluated, the amount of CEACAM6
was greater than that of CEACAM5. However, the homo-
geneity of expression and staining intensity varied
between tissue histotypes and between samples within the
same histological type. A summary of staining scores for
CEACAM5 and CEACAM6 for each tumor type and histo-
logical type is presented in Figure 1.
We evaluated 45 breast tumor cores: 30 infiltrating ductal
carcinoma, 8 papillary, 4 lobular, and 3 phyllodes.
CEACAM6 levels were higher than CEACAM5 levels for all
histotypes (P < 0.001). The highest CEACAM6 expression
was found in papillary (6.0 ± 2.1) > infiltrating ductal (5.1
± 2.5) > lobular (4.0 ± 0.8) > phyllodes (2.0 ± 1.0). The
differences between papillary and lobular breast cancers
were significant at the P < 0.01 level. The highest
CEACAM5 expression was found in papillary samples
(1.4 ± 1.4), but was not statistically different from infil-
trating ductal or lobular samples. Pyllodes breast cancer is
a stromal tumor, usually benign, and should therefore not
express CEACAM5 or CEACAM6. Examples of CEACAM5
and CEACAM6 staining for each histotype are found in
Figure 2.
CEACAM5 and CEACAM6 expression was assessed in 6
different lung cancers: 5 each of well, moderately and
poorly differentiated adenocarcinoma, 5 each of well,
moderately and poorly differentiated squamous carci-
Table 1: Number of Tissue Cores Analyzed for Each Histotype.
Tumor Histotype N Tumor Histotype N
Breast Infiltrating Ductal 30 Colon Adenocarcinoma 41
Papillary 8 Pancreas Well Diff 1
Lobular 4 Well-Mod Diff 16
Phyllodes 4 Mod Diff 2
Lung Well Diff Adeno 5 Mod-Poorly Diff 6
Mod Diff Adeno 5 Poorly Diff 1
Poorly Diff Adeno 5 Ovary Serous Adeno 5
Well Diff Squamous 5 Mucinous Adeno 4
Mod Diff Squamous 5 Clear Cell 5
Poorly Diif Squamous 5 Transitional Cell 5
Bronchioalveolar 3 Endometroid 4
Large-Cell 
Neuroendocrine
2B r e n n e r 4
Large-Cell 3 Yolk Sac 3
Small-Cell 2 Granulosa 3
Prostate Stage II 21 Dysgerminoma 3
Stage III 15
Stage IV 4BMC Cancer 2007, 7:2 http://www.biomedcentral.com/1471-2407/7/2
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noma, 3 each of large cell and bronchioalveolar, and 2
each of large cell neuroendocrine and small cell cancer.
Among these, adenocarcinoma expressed more
CEACAM6 than squamous cancer (P < 0.001). The high-
est CEACAM6 expression was found in moderately-differ-
entiated adenocarcinoma (7.8 ± 0.4) > well-differentiated
adenocarcinoma (7.3 ± 1.1) = bronchioalveolar (7.2 ±
0.8) > poorly-differentiated adenocarcinoma (6.8 ± 1.0) >
small-cell (5.5 ± 0.7) > well-differentiated squamous (5.2
± 1.0) > moderately-differentiated squamous cancer (4.9
± 1.1). CEACAM6 levels in large-cell (4.5 ± 0.9) and
poorly-differentiated squamous carcinomas (3.8 ± 1.3)
were similar to non-neoplastic lung tissue (P = NS), sug-
gesting that anti-CEACAM6 antibodies would not be
effective with these histotypes of lung cancer. The highest
expression of CEACAM5 was in small-cell lung cancer
specimens (5.5 ± 0.7), followed by large-cell neuroendo-
crine tumors (4.75 ± 3.18). Large-cell tumors were CEA-
negative and all adenocarcinomas and serous tumors
scored  ≤ 2.60. Typical examples of CEACAM5 and
CEACAM6 staining for each histological type are shown
in Figure 3.
Pancreatic cancer has been the most extensively studied
neoplasm with respect to CEACAM6 expression [28-35].
In this work, we evaluated CEACAM5 and CEACAM6 as a
function of tumor cell differentiation. One well-differen-
tiated, 3 well-moderately differentiated, 13 moderately-
differentiated, 2 moderately- to poorly-differentiated, and
7 poorly-differentiated tumor cores were studied. The
highest expression of CEACAM6 in pancreatic tumors was
found in moderately- (7.5 ± 0.7) > moderately-poor (5.9
± 1.9) = well-moderately differentiated (5.8 ± 1.8) >
poorly-differentiated tumors (5.1 ± 2.5) > well-differenti-
ated (4.0 ± 0.0) adenocarcinomas (P = NS between the
subtypes). Non-neoplastic pancreas CEACAM6 expres-
CEACAM5 and CEACAM6 staining of colon, ovarian, breast, lung, prostate and pancreatic tissue core specimens as a function  of tumor histotype is summarized Figure 1
CEACAM5 and CEACAM6 staining of colon, ovarian, breast, lung, prostate and pancreatic tissue core specimens as a function 
of tumor histotype is summarized. The results graphed represent the mean ± standard deviation for each histotype and anti-
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CEACAM5 and CEACAM6 expression in representative cases of infiltrating ductal, papillary, lobular and phyllodes breast  tumor cores Figure 2
CEACAM5 and CEACAM6 expression in representative cases of infiltrating ductal, papillary, lobular and phyllodes breast 
tumor cores.BMC Cancer 2007, 7:2 http://www.biomedcentral.com/1471-2407/7/2
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CEACAM5 and CEACAM6 expression in representative cases of well-, moderately-, poorly differentiated adenocarcinoma,  squamous carcinoma of lung, brochioalveolar, large-cell neuroendocrine, large-cell, and small-cell lung carcinoma cores Figure 3
CEACAM5 and CEACAM6 expression in representative cases of well-, moderately-, poorly differentiated adenocarcinoma, 
squamous carcinoma of lung, brochioalveolar, large-cell neuroendocrine, large-cell, and small-cell lung carcinoma cores.BMC Cancer 2007, 7:2 http://www.biomedcentral.com/1471-2407/7/2
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sion was 2.25 ± 0.5. The well-moderately, moderately,
and moderately-poor adenocarcinomas were significantly
higher than non-neoplastic pancreas (P < 0.001).
CEACAM6 expression did not correlate with disease stage.
Samples with high (8) and low (3–4) expression could be
found in stages IA-IB, IIA-IIB, and IV. CEACAM5 expres-
sion was lower than CEACAM6 for all histotypes; the
highest expression being found in moderately differenti-
ated tumors (4.0 ± 1.4) and the least in the moderate-poor
(0.92 ± 1.92) and poorly-differentiated (1.4 ± 1.5)
tumors. Only the moderately and the well-moderately dif-
ferentiated tumors expressed significantly more
CEACAM5 than non-neoplastic tissues (P < 0.002 and P <
0.005, respectively). Examples of CEACAM5 and
CEACAM6 staining for each histotype are presented in
Figure 4.
Eighteen stage-II, 15 stage-III, and 4 stage-IV prostate
tumor cores were stained for CEACAM5 and CEACAM6.
Gleason scores of 4 to 9 were represented in the stage-II
samples, and Gleason scores of 6 to 10 were found in the
stage-III specimens. All stage-IV samples were Gleason 9–
10. Expression did not correlate with Gleason score of the
sample within any stage. Similar expression of CEACAM6
was found in stage-II, -III, and -IV prostate cancer (3.3–
3.8), and was not significantly different from non-neo-
plastic prostate tissue (P = NS). CEACAM5 expression was
consistently below 0.9 for all stages of prostate cancer and
was not greater than expression levels in non-neoplastic
prostate tissue (0.5 ± 1.0; P = NS), suggesting that prostate
tumors would not be responsive to treatment with either
anti-CEACAM5 or anti-CEACAM6 antibody therapies.
Examples of CEACAM5 and CEACAM6 staining for each
histological type are shown in Figure 5.
Nine ovarian cancer types were included in these studied:
5 each of serous adenocarcinoma, mucinous adenocarci-
noma, clear cell carcinoma, and transitional cell carci-
noma; 4 each of endometrioid adenocarcinoma and
Brenner tumor; and 3 each of yolk sac tumor, granulosa
cell tumor, and dysgerminoma. The amount of CEACAM6
in ovarian cancer was highest in mucinous adenocarci-
noma (5.6 ± 1.7) > transitional cell (3.8 ± 1.6) > endome-
trioid (3.6 ± 2.8) > clear cell (3.4 ± 1.8) > yolk sac tumors
(2.5 ± 0.5). Mucinous tumor CEACAM6 expression was
significantly higher than transitional and endometroid (P
< 0.02), clear cell (P < 0.01), and yolk sac tumors (P <
0.005). Much lower levels were found in serous adenocar-
cinoma (1.8 ± 1.3) > Brenner tumor (1.3 ± 1.4) = dyger-
minoma (1.3 ± 1.5) > granulosa cell (0.7 ± 1.2). Normal
ovary samples were negative for CEACAM6. Thus, all
tumor histotypes expressed significantly more CEACAM6
than non-neoplastic ovary. The highest CEACAM5 expres-
sion also was found in the mucinous adenocarcinoma
type (1.6 ± 1.5). Expression of CEACAM5 in all other
ovarian samples scored below 0.6, and non-neoplastic
ovary scores were 0.5 ± 1.0. Mucinous CEACAM5 levels
were significantly higher than all other histotypes (P <
0.002 compared with endometroid and Brenner tumors,
and P < 0.001 compared with serous, clear cell, transi-
tional and yolk sac). Examples of CEACAM5 and
CEACAM6 staining for each histotype are found in Figure
6.
Much larger amounts of CEACAM6 were found in colon
adenocarcinoma (6.2 ± 1.4) compared with non-neoplas-
tic colon (3.0 ± 0.0; P < 0.002) and CEACAM6 expression
exceeded CEACAM5 expression (3.4 ± 0.5; P < 0.001).
Examples of CEACAM5 and CEACAM6 staining for each
histotype are found in Figure 7.
CEACAM6 expression has been associated with cell adhe-
sion, a key step in the metastatic cascade. We have shown
that antibody to CEACAM6 expression can block adhe-
sion [22]. Therefore, we assessed whether CEACAM6
expression was similar or different between matched pri-
mary colon and metastatic liver sites. In half of the
matched cases (N = 6), CEACAM6 expression was much
greater in the liver metastasis than in the primary colon
tumors, and in the remaining 6 cases, the amounts were
comparable between the primary and the metastatic liver
sites. Two examples of CEACAM6 staining for matched
normal colon tissue, primary colon tumor, and liver
metastases are shown in Figure 8.
In contrast to the higher expression off CEACAM6 in
many secondary liver sites from colon cancer, there was
no pattern for CEACAM6 expression between primary
tumor and lymph node metastases. For breast samples,
the lymph node sites had higher CEACAM6 expression in
7 pairs, lower CEACAM6 in 6, and no difference in 25
pairs. For lung samples, the lymph node sites had higher
CEACAM6 expression in 10 pairs, lower CEACAM6 in 11,
and no difference in 16 pairs. For colon samples, the
lymph node sites had higher CEACAM6 expression in 7
pairs, lower CEACAM6 in 10, and no difference in 11
pairs (Table 2).
Discussion
CEACAM5 and CEACAM6 are two tumor-associated anti-
gens that play important regulatory roles in cell adhesion
and in tumor cell chemosensitivity [36-38]. CEACAM6
overexpression independently predicts poor overall sur-
vival and poor disease-free survival, whereas CEACAM5
has not been related significantly to these outcomes [39].
Studies have shown that CEACAM5 affects expression of
various groups of cancer-related genes, especially cell cycle
and apoptotic genes, protecting colonic tumor cells from
various apoptotic stimuli, such as treatment with 5-fluor-BMC Cancer 2007, 7:2 http://www.biomedcentral.com/1471-2407/7/2
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CEACAM5 and CEACAM6 expression in representative cases of well-, moderately-well-, moderately-, moderately-poorly, and  poorly-differentiated adenocarcinoma and non-neoplastic pancreatic tissue cores Figure 4
CEACAM5 and CEACAM6 expression in representative cases of well-, moderately-well-, moderately-, moderately-poorly, and 
poorly-differentiated adenocarcinoma and non-neoplastic pancreatic tissue cores.BMC Cancer 2007, 7:2 http://www.biomedcentral.com/1471-2407/7/2
Page 9 of 15
(page number not for citation purposes)
CEACAM5 and CEACAM6 expression in representative stage II, stage III, and stage IV prostate cancer cases with non-neoplas- tic prostate tissues Figure 5
CEACAM5 and CEACAM6 expression in representative stage II, stage III, and stage IV prostate cancer cases with non-neoplas-
tic prostate tissues.BMC Cancer 2007, 7:2 http://www.biomedcentral.com/1471-2407/7/2
Page 10 of 15
(page number not for citation purposes)
CEACAM5 and CEACAM6 expression in representative non-neoplastic and adenocarcinoma cases of the colon Figure 6
CEACAM5 and CEACAM6 expression in representative non-neoplastic and adenocarcinoma cases of the colon.BMC Cancer 2007, 7:2 http://www.biomedcentral.com/1471-2407/7/2
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ouracil [40]. Therefore, CEACAM5 expression may be a
means for cancer cells to overcome apoptosis-inducing
therapies. Ordonez et al. have reported that expression of
both CEACAM5 and CEACAM6 plays a role in inhibiting
apoptosis of cells when deprived of their anchorage to the
extracellular matrix, a process known as anoikis [41].
Increased expression of CEACAM6 correlates with a
decrease in sensitivity to drugs, like gemcitabine [30]. Tar-
geting CEACAM5 and/or CEACAM6 may therefore be a
novel method of modulating cancer cell chemosensitivity
and apoptosis. It has been reported that siRNA to
CEACAM6 impairs resistance to anoikis and increases cas-
pase-mediated apoptosis of xenografted tumors [31].
Antibody-directed targeting of CEACAM6 may provide a
clinically feasible alternative to RNA interference silencing
to enhance responsive to chemotherapeutic agents in
those tumors that express CEACAM6.
To determine which solid tumors and histological types
would be most amenable to antibody blocking of
CEACAM5 and CEACAM6, we studied expression of these
antigens using tissue microarray analysis. To date, pancre-
atic and colonic cancer have been the focus of CEACAM6
expression in the literature [35,42]. Here, we have further
explored the expression of CEACAM6 in a panel of solid
tumors: breast, lung, ovary and prostate cancer, in addi-
tion to expanding on pancreatic and colonic tumors, and
used tissue microarrays to further define tumors that are
CEACAM6+ as a function of histological type in all six
solid tumor categories. Our results show that expression is
strongly dependent on the histotype of the tumor. Anti-
gen expression in some subtypes is 2–4-fold higher than
in normal tissues, while in others, expression is similar to
non-neoplastic tissues. Other investigators have reported
differences in the expression of select tumor antigens as a
CEACAM5 and CEACAM6 expression in representative cases of serous and mucinous adenocarcinoma, endometroid, yolk  sac, and transitional cell carcinoma of the ovary Figure 7
CEACAM5 and CEACAM6 expression in representative cases of serous and mucinous adenocarcinoma, endometroid, yolk 
sac, and transitional cell carcinoma of the ovary.
COLON
Background CEACAM5 CEACAM6
Non-Neoplastic
AdenocarcinomaBMC Cancer 2007, 7:2 http://www.biomedcentral.com/1471-2407/7/2
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Table 2: Comparison of CEACAM6 Expression between Primary and Lymph Node Metastases in Patients with Matched Specimens.
Number of Cases Where Primary Tissue 
Expression was Higher than Lymph Node 
Expression
Number of Cases Where Primary Tissue 
Expression was Lower than Lymph Node 
Expression
Number of Cases Where Primary Tissue 
and Lymph Node Expression was Similar
Breast 67 2 5
Lung 11 10 16
Colon 10 7 11
Immunohistochemical staining of four matched patient specimens from normal colon, primary colon carcinoma, and liver  metastasis stained with MN-15 anti-CEACAM6 Figure 8
Immunohistochemical staining of four matched patient specimens from normal colon, primary colon carcinoma, and liver 
metastasis stained with MN-15 anti-CEACAM6.BMC Cancer 2007, 7:2 http://www.biomedcentral.com/1471-2407/7/2
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function of histotype, e.g., TAG-72 in lung cancer [43],
VEGF in skin cancer [44], and BER EP4 and CA-125 in
ovarian cancer [45]. However, the results in this study are
the first to explore differences in both CEACAM5 and
CEACAM6 as a function of tumor histotype across six
tumor tissues.
The demonstration of higher CEACAM6 expression com-
pared with CEACAM5 across most solid tumors, and the
differential expression as a function of histotype, are
important observations for translating anti-CEACAM6
therapy to patients. However, we appreciate that addi-
tional supportive evidence from Western blots, RT-PCR/
Northern blots is needed. This semi-quantitative analysis
is intended only as an initial step towards elucidating the
importance of CEACAM6 as a tumor target in a variety of
solid tumors that extend the many important studies
reported for pancreatic cancer [28-35]. It also reveals that
expression level varies as a function of tumor histotype.
Since some histotypes only had 3–6 core samples and
considerable variability in antigen expression within the
histotype was noted, it is appropriate to include addi-
tional core tissues and to provide more quantitative sup-
port with other techniques on biopsy tissues in future
studies.
We have also addressed the expression pattern of
CEACAM6 in primary tumors and in matched metastases
in the same patients. Our results show that in half of the
clinical specimens, liver metastases had a much higher
expression of CEACAM6 than the primary colorectal
tumors, suggesting that in such patients, blocking adhe-
sion and invasion that results from CEACAM6 expression
might have influenced the ability of tumor cells to metas-
tasize, as we have in fact shown experimentally [4]. How-
ever, CEACAM6 expression in lymph node metastases was
similar to the amount of antigen in primary breast, colon
or lung tumor samples. The mechanism by which malig-
nant tumors invade lymphatics and metastasize to
regional lymph nodes appears to be regulated by VEGF-C
and VEGF-D induced lymphogenesis [46] and a chemok-
ine gradient. Directional movement is related to chemok-
ine receptor expression on tumor cells [47], but does not
involve members of the CEACAM family. In contrast,
CEACAM6 plays an important role in migration, invasion
and adhesion [31,34], steps that are important in the met-
astatic spread to secondary tissue sites other than lymph
nodes [48]. In fact, anti-adhesive molecules that disrupt
cell-matrix and cell-cell attachments have been proposed
as potential cancer therapeutics based on their ability to
interfere with motility, adhesion, and metastatic progres-
sion [22,36,49].
We have recently reported that the humanized anti-CEA
(CEACAM5) antibody, MN-14, can enhance the therapeu-
tic effects of two cytotoxic drugs used frequently in color-
ectal cancer therapy, fluorouracil and CPT-11, in both
subcutaneous and metastatic human colonic tumor cells
propagated in nude mice [50]. In another high CEA-
expressing human medullary thyroid cancer xenograft, we
have also shown that MN-14 anti-CEA IgG can inhibit
tumor cell growth and also augment the effects of dacar-
bazine, a drug that is active in this cancer type [51]. One
explanation may involve a role in antibody blocking
adhesion [38] and thereby chemosensitizing the tumor
cells.
In a series of provocative studies, Duxbury and associates
have shown that silencing CEACAM6 by siRNA: (a)
enhances cell anoikis, (b) increases caspase activation in
response to anchorage independent conditions, (c) down-
regulates the Akt cell survival pathway, (d) inhibits metas-
tasis in vivo, and (e) enhances gemcitabine induced
chemosensitivity [30,31,33-35]. Thus, in addition to
CEACAM5, CEACAM6 may also represent a useful thera-
peutic target. Blocking CEACAM6-mediated homotypic
and/or heterotypic adhesion may have anti-metastatic
and chemosensitizing effects. In ongoing preclinical ther-
apy studies, we are examining the therapeutic effects of
unconjugated anti-CEACAM6 antibody alone or com-
bined with standard chemotherapeutic agents in colon,
breast, and lung metastasis models. An alternative
approach is to develop an anti-CEACAM6 immunoconju-
gate as a therapeutic agent for CEACAM6+ tumors, as
described by Duxbury et al. [32]. In vitro targeting with an
anti-CEACAM6 antibody, followed by secondary saporin-
conjugated immunoglobulin (IgG), induced marked cyto-
toxicity via caspase-mediated apoptosis. In an in vivo
nude mouse xenograft model, this indirect immunotoxin
approach markedly suppressed pancreatic adenocarci-
noma tumor growth and enhanced tumor apoptosis.
Conclusion
Based on expression level, CEACAM6 may be a more
promising target for antibody-based anti-metastatic and
chemosensitizing therapy than CEACAM5 in all the solid
tumors studied. Furthermore, CEACAM6 may be a useful
antigen to target in select subtypes of solid tumors, with
the exception of prostate cancer, where no differentiation
was seen, compared to normal prostate. In colonic cancer,
CEACAM6 may play an important role in the develop-
ment of distant metastases.
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